Economic Burden of Cystic Fibrosis in Five Key European Countries: A Systematic Review


Verma R1, Telukuntla V2, Ahuja A3
1Lumanity, Delhi, DL, India, 2Lumanity, Delhi, India, 3Lumanity, Chandigarh, CH, India

Presentation Documents

OBJECTIVES: Cystic fibrosis (CF) is a rare, progressive disorder affecting the lungs, pancreas and other organs, and the most prevalent genetic condition among the Caucasian population. We aimed to identify comprehensive evidence on the economic burden of CF in five key European countries.

METHODS: We systematically searched Embase® and MEDLINE® databases via for English-language articles published from 2013–2023 reporting the economic burden (cost and resource use) of CF in children and adults in the UK, France, Germany, Italy and Spain.

RESULTS: Among 1,431 records screened, 11 studies were included reporting data for France (4), Italy (3), the UK (2), Germany (1) and all five countries (1). In France, total cost per patient increased sharply between 2006–2017 (mean €14,174 to €44,585). In Germany (2016), mean direct medical cost was €17,551 per patient-year, driven mainly by outpatient drug prescription (€12,869). In Italy, annual total cost per patient increased with age and lung disease severity from €4,164 in children aged ≤5 years to €30,123 in patients aged >5 years. In the UK, the key cost drivers were informal care (44.1 %), medications (14.5 %), acute hospitalizations (13.9 %), early retirement (9.1 %) and outpatient and primary healthcare visits (7.9 %). In Spain, mean total costs per patient was €32,911 in 2012; in children, total mean direct costs varied from €22,666–€60,412. In France, use of ivacaftor (CFTR modulator) reduced hospitalization rate from 0.47 hospitalizations per person-year to 0.22 after treatment. Children had higher direct costs than adults, and direct healthcare costs and resource utilization increased with disease duration.

CONCLUSIONS: Disease duration, hospitalizations and drug utilization are key drivers for cost and resource use in patients with CF. Total costs increased with patients’ level of dependence on others. Further measures are needed to alleviate this economic burden.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)




Economic Evaluation


Gastrointestinal Disorders, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now